Stocks of Arcutis Biotherapeutics Inc (NASDAQ:ARQT) traded higher last session on Wall Street, down -6.81% to $12.31.
ARQT stock price is now -8.71% away from the 50-day moving average and 17.78% away from the 200-day moving average. The market capitalization of the company currently stands at $1.44B.
With the price target of $19, H.C. Wainwright recently initiated with Buy rating for Arcutis Biotherapeutics Inc (NASDAQ: ARQT). On August 28, 2024, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $15, while ‘Mizuho’ rates the stock as ‘Buy’
In other news, Matsuda Masaru, insider sold 8,338 shares of the company’s stock on Feb 03 ’25. The stock was sold for $105,893 at an average price of $12.70. Upon completion of the transaction, the insider now directly owns 178,692 shares in the company, valued at $2.2 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 03 ’25, See Remarks Watanabe Todd Franklin sold 19,301 shares of the business’s stock. A total of $245,123 was realized by selling the stock at an average price of $12.70. This leaves the insider owning 804,129 shares of the company worth $9.9 million. A total of 11.99% of the company’s stock is owned by insiders.
During the past 12 months, Arcutis Biotherapeutics Inc has had a low of $6.05 and a high of $16.20. As of last week, the company has a debt-to-equity ratio of 1.33, a current ratio of 2.46, and a quick ratio of 2.38. The fifty day moving average price for ARQT is $13.4995 and a two-hundred day moving average price translates $10.432475 for the stock.
The latest earnings results from Arcutis Biotherapeutics Inc (NASDAQ: ARQT) was released for 2024-09-30. The net profit margin was -140.97% and return on equity was -192.31% for ARQT. The company reported revenue of $44.76 million for the quarter, compared to $38.11 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17.44 percent.
